OSCR

Integrated Virtual Screening and Molecular Electrostatic Surface Potential Descriptors for Predicting BACE1 Inhibitor Interactions in Alzheimer's Disease.

Overview

Authors: Yoanna Alvarez-Ginarte1, Rafael López2, José Manuel García de la Vega2, Ignacio De Ema2, Daniel Alpízar-Pedraza3
  1. Universidad de la Habana, Facultad de Química, Havana 10400, Cuba
  2. Universidad Autónoma de Madrid, Química Física Aplicada, Madrid, 28049 Madrid, Spain
  3. Center for Pharmaceuticals Research and Development (CIDEM), La Habana 10400, Cuba
Journal: ACS omega, volume 11, issue 32, pages 47739-47753
Dates: received 18 March 2026; accepted 17 July 2026; published online 7 August 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.1021/acsomega.6c02969 · PMID 42626185 · PMCID PMC13491998 · OpenAlex W7201883493
Open access: gold, a free copy (OpenAlex)
Categories: Alzheimer's / dementia (population)
Methods: Smoothing, state filtering, decompositions, Machine learning
Topic: Computational Drug Discovery Methods (Drug Discovery, Pharmacology, Toxicology and Pharmaceutics), according to OpenAlex
Funding: Ministerio de Ciencia, Innovación y Universidades (PID2024-156686NB-I00, PID2024); Universidad Autónoma de Madrid; Universidad de La Habana; Fundación Carolina (2024-2025)
Citations: not cited yet (Europe PMC); 69 references in the paper

Abstract

Developing brain-penetrant BACE1 inhibitors remains a major challenge in Alzheimer’s disease. Unlike conventional studies focusing solely on binding affinity, this work presents an integrated computational pipeline that prioritizes both potency and pharmacokinetic developability from the outset. A robust quantitative structure–activity relationship (QSAR) model was built for 41 N-(pyridin-3-yl)­picolinamide derivatives using Molecular Electrostatic Surface Potential (MESP) descriptors. Principal component analysis identified three key electrostatic features – mean MESP, variance of negative MESP, and number of local MESP maxima/minima as drivers of BACE1 inhibitory activity. A key novelty is the early integration of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) filtering, using ADMETlab 3.0, to ensure blood-brain barrier (BBB) permeability and low P-glycoprotein efflux properties whose absence contributed to the failure of several clinical BACE1 inhibitors. Only compound N-[3-[(1S,5S,6S)-3-amino-1-(difluoromethyl)-5-(fluoromethyl)-2-thia-4-azabicyclo[4.1.0]­hept-3-en-5-yl]-4-fluorophenyl]-5-chloropyrazine-2-carboxamide (5) simultaneously satisfied the criteria for high predicted potency, favorable BBB penetration, low PgP efflux, and good synthetic accessibility. Molecular docking revealed that compound 5 binds strategically to the S1 and S3 substrate-recognition pockets through hydrogen bonds with THR280, GLN121, LYS155, as well as a halogen interaction with ARG283, while avoiding direct interaction with the catalytic dyad. This binding mode balances affinity and permeability, distinguishing compound 5 from clinically unsuccessful inhibitors. The practical implication is a rational framework that rapidly prioritizes candidates with high potency and favorable Central Nervous System (CNS) drug-like properties, thereby reducing the risk of late-stage attrition. All predictions are computational and require experimental validation (enzymatic, cellular, and in vivo) before any translational claims can be made. Thus, combining QSAR, ADMET, and molecular docking with an early emphasis on BBB penetration offers a time-efficient strategy for CNS drug discovery against Alzheimer’s disease.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 3, 28 September 2026

  • Funding: added Ministerio de Ciencia, Innovación y Universidades: PID2024-156686NB-I00, PID2024; Universidad Autónoma de Madrid; Universidad de La Habana; Fundación Carolina: 2024-2025

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 5 authors, 66 references.

Cite

This paper

Alvarez-Ginarte, Y., López, R., García de la Vega, J. M., De Ema, I., & Alpízar-Pedraza, D. (2026). Integrated Virtual Screening and Molecular Electrostatic Surface Potential Descriptors for Predicting BACE1 Inhibitor Interactions in Alzheimer's Disease. ACS omega, 11(32), 47739-47753. https://doi.org/10.1021/acsomega.6c02969

BibTeX

@article{alvarezginarte2026integrated,
author = {Alvarez-Ginarte, Yoanna and López, Rafael and García de la Vega, José Manuel and De Ema, Ignacio and Alpízar-Pedraza, Daniel},
title = {{Integrated Virtual Screening and Molecular Electrostatic Surface Potential Descriptors for Predicting BACE1 Inhibitor Interactions in Alzheimer's Disease}},
journal = {ACS omega},
year = {2026},
month = aug,
volume = {11},
number = {32},
pages = {47739--47753},
publisher = {American Chemical Society},
issn = {2470-1343},
doi = {10.1021/acsomega.6c02969},
url = {https://doi.org/10.1021/acsomega.6c02969},
pmid = {42626185},
pmcid = {PMC13491998}
}

RIS

TY - JOUR
AU - Alvarez-Ginarte, Yoanna
AU - López, Rafael
AU - García de la Vega, José Manuel
AU - De Ema, Ignacio
AU - Alpízar-Pedraza, Daniel
TI - Integrated Virtual Screening and Molecular Electrostatic Surface Potential Descriptors for Predicting BACE1 Inhibitor Interactions in Alzheimer's Disease
T2 - ACS omega
J2 - ACS Omega
PY - 2026
DA - 2026/08/07
VL - 11
IS - 32
SP - 47739
EP - 47753
SN - 2470-1343
PB - American Chemical Society
DO - 10.1021/acsomega.6c02969
UR - https://doi.org/10.1021/acsomega.6c02969
LA - en
ER -

CSL-JSON

{
"id": "10.1021/acsomega.6c02969",
"type": "article-journal",
"title": "Integrated Virtual Screening and Molecular Electrostatic Surface Potential Descriptors for Predicting BACE1 Inhibitor Interactions in Alzheimer's Disease",
"container-title": "ACS omega",
"author": [
{
"family": "Alvarez-Ginarte",
"given": "Yoanna"
},
{
"family": "López",
"given": "Rafael"
},
{
"family": "García de la Vega",
"given": "José Manuel"
},
{
"family": "De Ema",
"given": "Ignacio"
},
{
"family": "Alpízar-Pedraza",
"given": "Daniel"
}
],
"container-title-short": "ACS Omega",
"volume": "11",
"issue": "32",
"page": "47739-47753",
"DOI": "10.1021/acsomega.6c02969",
"PMID": "42626185",
"PMCID": "PMC13491998",
"ISSN": "2470-1343",
"publisher": "American Chemical Society",
"URL": "https://doi.org/10.1021/acsomega.6c02969",
"language": "en",
"issued": {
"date-parts": [
[
2026,
8,
7
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1021/acs.jcim.5c00724 [code]
Graph Convolutional Neural Network-Enabled Frontier Molecular Orbital Prediction: A Case Study with Neurotransmitters and Antidepressants.
Journal: Journal of chemical information and modeling
In common: 2 references
[2] doi:10.1038/s41598-025-22955-7 [code]
Identification of novel neuraminidase 1 modulators as potential therapeutics for Alzheimer's disease using virtual screening and molecular dynamics simulations.
Journal: Scientific reports
In common: Alzheimer's / dementia, 2 references
[3] doi:10.3390/ijms27021008
Design, Synthesis, and Biological Evaluation of Novel Acetylcholinesterase and β-Secretase 1 Inhibitors.
Journal: International journal of molecular sciences
In common: Alzheimer's / dementia, 2 references
[4] doi:10.1021/acs.molpharmaceut.3c00700 [code]
Role of Transporters and Enzymes in Metabolism and Distribution of 4-Chlorokynurenine (AV-101).
Journal: Molecular pharmaceutics
In common: 2 references
[5] doi:10.1038/s41598-025-99751-w [code]
Identification of novel TMEM16A blockers through integrated virtual screening, molecular dynamics, and experimental studies.
Journal: Scientific reports
In common: 2 references
[6] doi:10.1186/s13065-024-01316-x [code]
Combined machine learning models, docking analysis, ADMET studies and molecular dynamics simulations for the design of novel FAK inhibitors against glioblastoma.
Journal: BMC chemistry
In common: 2 references
[7] doi:10.1038/s41598-023-32043-3
New insights into the neuroprotective and beta-secretase1 inhibitor profiles of tirandamycin B isolated from a newly found Streptomyces composti sp. nov.
Journal: Scientific reports
In common: 2 references
[8] doi:10.1186/s13195-024-01574-w
Gene-variant specific effects of plasma amyloid-β levels in Swedish autosomal dominant Alzheimer disease.
Journal: Alzheimer's research & therapy
In common: Alzheimer's / dementia, 1 reference
[9] doi:10.3389/fphar.2022.893244
Yuan-Zhi decoction in the treatment of Alzheimer's disease: An integrated approach based on chemical profiling, network pharmacology, molecular docking and experimental evaluation.
Journal: Frontiers in pharmacology
In common: Alzheimer's / dementia, 1 reference
[10] doi:10.1155/2021/7158444
The Combination of <i>β</i>-Asarone and Icariin Inhibits Amyloid-<i>β</i> and Reverses Cognitive Deficits by Promoting Mitophagy in Models of Alzheimer's Disease.
Journal: Oxidative medicine and cellular longevity
In common: Alzheimer's / dementia, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.